Abstract
COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL-6R) antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL-6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL-6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm.
Keywords: IL-6R antagonist; cytokine storm; sarilumab; therapeutic option; tocilizumab.
【저자키워드】 Cytokine storm, Tocilizumab, sarilumab, IL-6R antagonist, therapeutic option, 【초록키워드】 COVID-19, coronavirus, clinical trial, therapy, Mortality, Tocilizumab, cytokine, Cytokine storm syndrome, therapeutic, Patient, receptor, Critical, patients, COVID-19 patients, acute respiratory syndrome, IL-6R, physician, researcher, antagonist, humanized monoclonal antibody, ENhance, reduce, the cytokine storm, 【제목키워드】 therapy, Cytokine storm syndrome, IL-6 receptor, SARS-CoV-2 infected patient,